ArticleCureus2024
Anti-MDA5 Positive Juvenile Dermatomyositis With Macrophage Activation Syndrome: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are several types of inflammatory myopathies, including juvenile dermatomyositis (JDM), which is characterized by muscle inflammation that can eventually lead to weakness. A devastating complication of JDM is macrophage activation syndrome (MAS), although reports of MAS in JDM patients are limited. Additionally, cases of JDM associated with positive anti-MDA5 are rare and represent a fatal subtype of inflammatory myopathies, with a significant risk of lung impairment. This case report discusses a six-year-old girl presenting with proximal muscle weakness and cutaneous changes, including heliotrope rash and Gottron's papules, who was diagnosed with JDM. Muscle involvement was confirmed through MRI of the thigh muscles. Laboratory findings revealed elevated aldolase, hepatitis, high lactate dehydrogenase, and hyperferritinemia, leading to a diagnosis of JDM complicated by MAS. Pulse steroid therapy combined with cyclosporine was initiated, and she showed significant improvement initially. However, she later tested positive for anti-MDA5 antibodies, a marker associated with a poor prognosis. Highlighting MAS as a potential complication in JDM cases with positive anti-MDA5 antibodies can help physicians recognize this outcome and consider it in the differential diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.